Publications by authors named "A B Leiter"
Article Synopsis
- This report analyzes the trends in statin prescriptions for breast cancer survivors with diabetes, a group at significant risk for cardiovascular disease (CVD).
- The study utilized data from the SEER cancer registry and Medicare claims, evaluating prescription rates based on various factors like age and race.
- Results indicated that 68% of participants received statin prescriptions, with an increasing trend over the years and a notable racial disparity, suggesting the need for improved prescription practices in this high-risk population.
The global burden of lung cancer: current status and future trends.
Nat Rev Clin Oncol
September 2023
Lung cancer is the leading cause of cancer-related death worldwide. However, lung cancer incidence and mortality rates differ substantially across the world, reflecting varying patterns of tobacco smoking, exposure to environmental risk factors and genetics. Tobacco smoking is the leading risk factor for lung cancer.
View Article and Find Full Text PDFBackground: Diabetes is a common comorbidity in patients with early-stage non-small cell lung cancer (NSCLC), a growing population due to increased LC screening. However, it is unknown if diabetes is associated with less aggressive NSCLC treatment and worse NSCLC outcomes. This study aimed to investigate treatment patterns and outcomes of older patients with Stage I NSCLC and diabetes.
View Article and Find Full Text PDFBackground: Randomized controlled trials (RCTs) have demonstrated a survival benefit for adjuvant platinum-based chemotherapy after resection of locoregional non-small cell lung cancer (NSCLC). The relative benefits and harms and optimal approach to treatment for NSCLC patients who have major comorbidities (chronic obstructive pulmonary disease [COPD], coronary artery disease [CAD], and congestive heart failure [CHF]) are unclear, however.
Methods: We used a simulation model to run in-silico comparative trials of adjuvant chemotherapy versus observation in locoregional NSCLC in patients with comorbidities.
Objectives: Response to immune checkpoint inhibitor (ICI) remains limited to a subset of patients and predictive biomarkers of response remains an unmet need, limiting our ability to provide precision medicine. Using real-world data, we aimed to identify potential clinical prognosticators of ICI response in solid tumor patients.
Methods: We conducted a retrospective analysis of all solid tumor patients treated with ICIs at the Mount Sinai Hospital between January 2011 and April 2017.